Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pemetrexed

Pemetrexed Am J Cancer 2003; 2 (5): 371-372 GUEST COMMENTARIES 1175-6357/03/0005-0371/$30.00/0 © Adis Data Information BV 2003. All rights reserved. assays, cisplatin-resistant MPM was sensitive to pemetrexed and A Viewpoint by Mark McKeage and in human tumor xenografts combining pemetrexed and cisplatin Timothy Christmas has greater-than-additive activity compared with either drug alone. The University of Auckland, Auckland, New Zealand Large, randomized, multicenter phase III trials have been con- ducted comparing the efficacy of pemetrexed combined with Pemetrexed is an antifolate drug with well-documented clinical cisplatin to cisplatin alone in patients with MPM and that of activity in a range of solid tumors. Like other antifolate drugs, pemetrexed monotherapy to docetaxel as second-line treatment in pemetrexed and its polyglutamated metabolites inhibit several patients with NSCLC. Overall survival time, progression-free folate-dependent enzymes involved in nucleic acid biosynthesis. survival time, and tumor response were significantly improved by However, unlike methotrexate, which inhibits mainly dihydrofo- pemetrexed combination treatment in patients with MPM. Peme- late reductase, pemetrexed-induced metabolic effects are exerted trexed and docetaxel were equivalent as second-line therapy in by the inhibition of thymidylate synthase and other folate-requir- patients with NSCLC, but moderate-to-severe toxicity was less ing enzymes. frequent with pemetrexed. Pemetrexed use was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Pemetrexed

Abstract

Am J Cancer 2003; 2 (5): 371-372 GUEST COMMENTARIES 1175-6357/03/0005-0371/$30.00/0 © Adis Data Information BV 2003. All rights reserved. assays, cisplatin-resistant MPM was sensitive to pemetrexed and A Viewpoint by Mark McKeage and in human tumor xenografts combining pemetrexed and cisplatin Timothy Christmas has greater-than-additive activity compared with either drug alone. The University of Auckland, Auckland, New Zealand Large, randomized, multicenter phase III trials have been...
Loading next page...
 
/lp/springer-journals/pemetrexed-9x3cp0CbxG
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302050-00010
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2003; 2 (5): 371-372 GUEST COMMENTARIES 1175-6357/03/0005-0371/$30.00/0 © Adis Data Information BV 2003. All rights reserved. assays, cisplatin-resistant MPM was sensitive to pemetrexed and A Viewpoint by Mark McKeage and in human tumor xenografts combining pemetrexed and cisplatin Timothy Christmas has greater-than-additive activity compared with either drug alone. The University of Auckland, Auckland, New Zealand Large, randomized, multicenter phase III trials have been con- ducted comparing the efficacy of pemetrexed combined with Pemetrexed is an antifolate drug with well-documented clinical cisplatin to cisplatin alone in patients with MPM and that of activity in a range of solid tumors. Like other antifolate drugs, pemetrexed monotherapy to docetaxel as second-line treatment in pemetrexed and its polyglutamated metabolites inhibit several patients with NSCLC. Overall survival time, progression-free folate-dependent enzymes involved in nucleic acid biosynthesis. survival time, and tumor response were significantly improved by However, unlike methotrexate, which inhibits mainly dihydrofo- pemetrexed combination treatment in patients with MPM. Peme- late reductase, pemetrexed-induced metabolic effects are exerted trexed and docetaxel were equivalent as second-line therapy in by the inhibition of thymidylate synthase and other folate-requir- patients with NSCLC, but moderate-to-severe toxicity was less ing enzymes. frequent with pemetrexed. Pemetrexed use was

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.